Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

E: Neuropsychopharmacology > Alzheimer’s disease and its treatment > Flashcards

Alzheimer’s disease and its treatment Flashcards

(68 cards)

Start Studying
1
Q

Dementia?

A

A syndrome

Usually of a chronic or progressive nature.

Deterioration in cognitive function- ie the ability for process thought.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What does dementia effect?

A

Affects memory

Thinking

Orientation

Comprehension

Learning capacity

Lanaguage etc

Consciousness is not effected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What percentage is dementia surferrers caused by alzheimers?

A

60-70%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Mixed dementia?

A

Mixture of different types of dementia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the numbers of dementia sufferers expected to do every 25 years

A

Numbers expected to double

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

AD brain?

A

Brain has shrunk

Extracellular plaques and intracellular neurofibrillary tangles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Name the 6 important stages of the history of AD research?

A
  1. Chloinergic hypothesis
  2. Discovery of amyloid and tau.
  3. Oxidative damage.
  4. Genetic mutations
  5. Importance of inflammation
  6. Immunotherapy (antibodies against amyloid)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What happens to an Alzheimers brain?

A

Severe cell loss.

Spreads from hippocampus right through into the cerebellum and into the spinal cord.

Damge to proteins and protein accumulations

Damage to lipids and inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Late onset alzheimers?

A

>95% of dementia cases.

>65 yo.

Genetic link with APOE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Early onset Alzheimers disease?

A

5% of AD cases

Present in >65 yo.

Genetic link with APP, PSEN1, PSEN2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Apolipoprotein E (ApoE)

A

Major component of very low-density lipoproteins.

Remove excess cholesterol from the blood and carry it to the liver.

Most abundantly produced apoprotein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ApoE role?

A

Cholesterol and lipid delivery to neurones

Cholesterol transport to the blood to the liver for processing.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What secretes ApoE?

A

Secreted by glial cells in nascent high-density lipoproteins-like particles.

They contain phospholipids and cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the ApoE concentration in cerebrospinal fluid?

A

5 µg/ml

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

ApoE receptors?

A

LDLR (low desity lipoprotein receptor)

LRP1 (LDLR-related protein)

Undergo endocytosis to transport ligands from the cell surface to intracellular compartments.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

ApoE is?

How many forms of it?

A

glycoprotein

3 common forms (each differ from each other by 1/2 AAs)

ApoE2

ApoE3

ApoE4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

ApoE4

A

Risk of AD is high with one allelle and must greater with two alleles.

60% are ApoE carriers.

Reduces the age of this onset disease.

More extensive plaques and tangles.

Higher CSF concentration of soluble Abeta.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

ApoE effects on amyloid?

A

ApoE contains paritcles sequester Aβ that modulates the cellular uptake of the complex by receptor-mediated endocyotsis.

Modulate Aβ removal from the brain by systemic circulation (transport across the blood-brain barrier)

ApoE facilitates the binding and internalisation of Aβ or its clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Targeting ApoE?

Name the 5 Therapeutic approaches

A
  1. Conversion of ApoE4 to ApoE3.
  2. Increase the lipidation.
  3. Interference interaction between ApoE4 and amyloid beta (Aβ).
  4. Reversal of the effects of ApoE4.
  5. Gene transfer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What does ApoE3 and ApoE4 do?

A

AS1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

TREM2?

A

Triggering receptor expressed on myeloid cells 2.

increaase chance of AD by 3 fold

Rare

Found in microglia.

Related to parkinson’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

PLD3?

A

little known on function.

Overexpression leads to reduction in Aβ levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Name the 3 dominatly inherited mutations involved in amyloid processing?

A
  1. β-amyloid precusor protein
  2. PSEN1
  3. PSEN2
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

β-amyloid precursor protein (APP)?

A

Alternatively spliced to produce 3 transcripts

APP695, APP751, APP770

Proteolytic processing of APP leads to production of rfragments and the amyloidogenic pathways.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
PSEN1/2?
PSEN1: Located at chromosome 14 PSEN2: located at chromosome 1 PSEN1/2 are important for the γ-secretase complex. This cleaves APP into Aβ fragments
26
3 main pathways causing AD?
1. The immune system and inflammatory response 2. Cholesterol and lipid metabolism 3. Endosomal vesicle recycling
27
What are the 5 major hypotheses that causes AD?
1. Cholinergic and glutamatergic 2. Amyloid and Tau 3. Oxidative stress 4. Inflammation 5. New targets
28
Cholinergic hypothesis?
Selective loss of cholinergic projections from hippocampus and frontal campus. Muscarinic receptor antagonist coud mimic the deficits. Reversed using AChE inhibitors
29
Name the 4 current therapeutics?
1. Tacrine 2. Donepezil 3. Galantamine 4. Rivastigmine
30
Tacarine?
Short half life Need to take 4 times a day (not great with memory problems)
31
Donepezil?
70Hr half life
32
Galantamine?
Once a day Interacts with AChRs
33
Rivastigmine?
transdermal patch 2x daily
34
Acetylcholinesterase inhibitors? (AChE inhibitors)
Show consistent, small treatment effects in mild AD Effects are only temporary. Effects seen within 4 months
35
Glutamate/Calcium Dysregulation hypothesis?
Aβ oligomers enhance the presynaptic release of glutamate. Blocks glutamate uptake by astrocytes though glutamate transporters. Leads to Tau phosphorylation and neuronal death.
36
Memantine?
A voltage-dependent, non-competitive NMDA receptor antagonist. Used to manage AD- for peopel that cannot take AChE inhibitors
37
Amyloid hypthoesis? 3 therpeutic strategies?
1. Prevent Aβ production 2. Prevent aggregation 3. Promote removal
38
Prevent Aβ production?
beta-secretase inhibitor gamm-secretase inhibitor
39
Prevent aggregation?
A β oligomerisation inhibitors. Tau aggregation inhibitors
40
Promote removal?
Vaccines
41
Name the 3 drug trails targeting amyloid processing?
1. alpha-secretase inducer 2. gamm-secretase inhibitor 3. BACE inhibitors:
42
Tau?
Highly soluble microtubule-binding protein. Mutations in tau cause frontotemporal dementia. Hyperphosporylation of tau destablises micrtubules, causing neuronal dysfunction.
43
Oxidative stress?
Oxygen helps us burn sugar to produce energy. Need antioxidant defences so it does not damage cell strucutres. Oxidative stress occurs when free radical production outstrips the ability of the cell to neutralise it
44
Name the 3 defences against oxidants?
1. Glutathione system 2. Superoxide dismutase 3. Catalase
45
Name the other 7 causes of oxidative stress?
1. Ageing 2. Environmental pollution 3. Food contaminants 4. Cigarettes 5. Amyloid 6. Inflammation 7. Injury
46
Oxidative stress in AD?
Implicated in the pathology of AD. Free radical damage to DNA is evident early in AD.
47
Amyloid and tau patholgies
Alzheimer's disease (AD) is characterized by extracellular deposition of β-amyloid (Aβ) intracellular accumulation of hyperphosphorylated, aggregated tau as neurofibrillary tangles
48
Name the 2 antioxidants that are used as treatment for dementia?
1. **Vitamin C**- does not get into the brain- metabolites of vitamin C (DHA) can get into the brain and protect it from a stroke. DHA is broken down rapidly. 2. **Vitamin E:** does get into the brain however the conc is tighly controlled and even high dosage will not increase the brain concentration.
49
Inflammation?
Use of anti-inflammatory agents. People with arthritis less likely to get AD. NSAIDS did nothing Statin?
50
What encodes for nAChRs?
8 alpha (alpha 2-\>9) 3 beta ( beta2-\>4)
51
Heteromeric nAChRs receptor is formed be?
alpha 2-6 beta 2-4 subunits
52
Homomeric nAChRs is formed by?
alpha 7-9 subunits
53
80% of nAChRs in the CNS are?
alpha 4 beta 2
54
10% of the nAChRs in the CNS are?
alpha 7
55
Early AD: Aβ and alpa7 nACh recepotr
the expression overlaps. Aβ induces expressio of the alpha7 nACh receptor
56
alpha7 nACh receptor activation
Facilitates neurotransmission and synaptic plasticity. Induces LTP. Supports learning and memory.
57
alpha7 interaction with Aβ
found in amyloid plaques. Can mediate internalisation of aβ Mediates inflammatory response to Aβ Blocks amyloid toxicity.
58
Agonist of the alpha7 nicotinic repector? Positive and negative effects?
For: conitive enhancing, anti-inflmmatoyr, induces amyloid phagocytosis. Against: rapid desensitisation
59
Antagonist for the alpga7 nicotinic receptor: Positive and negative effects?
**For**: block adverse effects of Aβ- intracellular accumulation and toxicity. **Against**: not cognitive enhacing, block synpatic plasticity.
60
Modelling MCI
Impairments in olfactory discrimination and odur recognition memory. Patients with MCI combined with olfactory deficienceies are highly to progress to AD.
61
OST?
Odour span task. Based on the digit span task. Model requires the idenfitication of a novel oduour from an expanding list of previously experienced odours.
62
Humanin?
The peptide is made by the mitocondria and exported to neighbouring cells to protect amyloid toxicity and ischemic. Used as a biomarker for early AD. Reverses defecits of damage and oxidative stress. Not expressed noramlly- only when there is damage on surviving neurones.
63
IGFBP3?
Involved in amyloid clearance Also enduces heart problems and cancer
64
HNG drug target?
HNG: analog of human increases span length at microscopic doses. Improves olfactory working memory
65
Current AD treatments?
Provide limited (9-12mnths) respite in a subpopulation of patients Afford limited symptomatic relief
66
Diseas-modifying treatments?
Pathological hallmarks appear to be tombstome marks rather than signpost to the underlying disease.
67
A model for MCI?
Deficits in olfactory working emory precede amyloid deposition in TG2576
68
OST examples?
Demonstarte cognitive enhancing. Nicotine and a7 nACh receptor agonist Humanin

E: Neuropsychopharmacology (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions